Mechanisms of vasodilation to PTH 1–84, PTH 1–34, and PTHrP 1–34 in rat bone resistance arteries

Osteoporosis International

Volumn 27, Issue 5, 2016, Pages 1817-1826

  Benson, T ^a   Menezes, T ^a   Campbell, J ^a   Bice, A ^b   Hood, B ^b   Prisby, R ^b  

^a UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

^b UNIVERSITY OF DELAWARE   (United States)

Author keywords

Bone resistance arteries; PTH; Vasodilation

Indexed keywords

CALPHOSTIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; NITROPRUSSIDE SODIUM; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE[1-34]; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE C; PARATHYROID HORMONE-RELATED PROTEIN (1-34); PEPTIDE FRAGMENT; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE BLOOD FLOW; BONE METABOLISM; ENDOTHELIUM CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE CELL; VASODILATATION; ANIMAL; ARTERY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; FEMUR; PHYSIOLOGY; TISSUE CULTURE TECHNIQUE; VASCULAR ENDOTHELIUM; VASCULARIZATION; WISTAR RAT;

ANIMALS; ARTERIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMUR; MALE; NITROPRUSSIDE; PARATHYROID HORMONE; PARATHYROID HORMONE-RELATED PROTEIN; PEPTIDE FRAGMENTS; RATS, WISTAR; TERIPARATIDE; TISSUE CULTURE TECHNIQUES; VASODILATION; VASODILATOR AGENTS;

EID: 84953232735     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3460-z     Document Type: Article

References (56)

1. Guyton A, Hall JE (2006) Textbook of medical physiology. Elsevier, Philadelphia
2. Thiede M, Rodan GA (1988) Expression of a calcium-mobilizing parathyroid hormone-like peptide in lactating mammary tissue. Science 242(4876):278–280
3. Riddle R, Macica CM, Clemens TL (2008) Vascular, cardiovascular, and neurological actions of parathyroid-related protein. In: Bilezikian J, Raisz LG, Martin TJ (eds) Principles of Bone Biology, vol 1, Elsevier. San Diego, CA, pp 733–748
4. Takahashi K, Inoue D, Ando K, Matsumoto T, Ikeda K, Fujita T (1995) Parathyroid hormone-related peptide as a locally produced vasorelaxant: regulation of its mRNA by hypertension in rats. Biochem Biophys Res Commun 208(1):447–455
5. Kousteni S, Bilezikian JP (2008) Cellular actions of parathyroid hormone. In: Bilezkian JP, Raisz LG, Martin TJ (eds) Principals of Bone Biology, vol 1, 3rd edn. Acdemic Press, San Diego, CA, pp 639–656
6. Hansen S, Beck Jensen JE, Rasmussen L, Hauge EM, Brixen K (2010) Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: a case-control study using HR-pQCT. J Bone Miner Res 25(9):1941–1947
7. Horwitz M, Tedesco MB, Sereika SM, Prebehala L, Gundberg CM, Hollis BW, Bisello A, Garcia-Ocaña A, Carneiro RM, Stewart AF (2011) A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover. J Bone Miner Res 26(9):2287–2297
8. Prisby R, Guignandon A, Vanden-Bossche A, Mac-Way F, Linossier MT, Thomas M, Laroche N, Malaval L, Langer M, Peter ZA, Peyrin F, Vico L, Lafage-Proust MH (2011) Intermittent PTH(1–84) is osteoanabolic but not osteoangiogenic and relocates bone marrow blood vessels closer to bone-forming sites. J Bone Miner Res 26(11):2583–2596
9. Prisby R, Menezes T, Campbell J (2013) Vasodilation to PTH (1–84) in bone arteries is dependent upon the vascular endothelium and is mediated partially via VEGF signaling. Bone 54(1):68–75
10. Stewart A, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM (2000) Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1–34, parathyroid hormone-related protein 1–36, and SDZ-parathyroid hormone 893. J Bone Miner Res 15(8):1517–1525
11. de Castro L, Lozano D, Portal-Núñez S, Maycas M, De la Fuente M, Caeiro JR, Esbrit P (2012) Comparison of the skeletal effects induced by daily administration of PTHrP (1–36) and PTHrP (107–139) to ovariectomized mice. J Cell Physiol 227(4):1752–1760
12. Horwitz M, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF (2003) Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88(2):569–575
13. Fogelman I, Fordham JN, Fraser WD, Spector TD, Christiansen C, Morris SA, Fox J (2008) Parathyroid hormone (1–84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy. Calcif Tissue Int 83(2):85–92
14. Silverman S, Nasser K (2011) Teriparitide update. Rheum Dis Clin North Am 37(3):471–477
15. Moen M, Scott LJ (2006) Recombinant full-length parathyroid hormone (1–84). Drugs 66(18):2371–2381
16. Leder B, O’Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G (2015) Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 100(2):697–706
17. Ureña P, Kong XF, Abou-Samra AB, Jüppner H, Kronenberg HM, Potts JT Jr, Segre GV (1993) Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinology 133(2):617–623
18. Okano K, Wu S, Huang X, Pirola CJ, Juppner H, Abou-Samra AB, Segre GV, Iwasaki K, Fagin JA, Clemens TL (1994) Parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor and its messenger ribonucleic acid in rat aortic vascular smooth muscle cells and UMR osteoblast-like cells: cell-specific regulation by angiotensin-II and PTHrP. Endocrinology 135(3):1093–1099
19. Jiang B, Morimoto S, Fukuo K, Hirotani A, Tamatani M, Nakahashi T, Nishibe A, Niinobu T, Hata S, Chen S, Ogihara T (1996) Parathyroid hormone-related protein inhibits indothelin-1 production. Hypertension 27(3 Pt 1):360–363
20. Jiang B, Morimoto S, Yang J, Niinoabu T, Fukuo K, Ogihara T (1998) Expression of parathyroid hormone/parathyroid hormone-related protein receptor in vascular endothelial cells. J Cardiovasc Pharmacol 31(Suppl 1):S142–S144
21. Charbon G, Hulstaert PF (1974) Augmentation of arterial hepatic and renal flow by extracted and synthetic parathyroid hormone. Endocrinology 95(2):621–626
22. Pang P, Janssen HF, Yee JA (1980) Effects of synthetic parathyroid hormone on vascular beds of dogs. Pharmacology 21(3):213–222
23. Pang P, Tenner TE Jr, Yee JA, Yang M, Janssen HF (1980) Hypotensive action of parathyroid hormone preparations on rats and dogs. Proc Natl Acad Sci U S A 77(1):675–678
24. Pang P, Yang MC, Shew R, Tenner TE Jr (1985) The vasorelaxant action of parathyroid hormone fragments on isolated rat tail artery. Blood Vessel 22(2):57–64
25. Rashid G, Bernheim J, Green J, Benchetrit S (2007) Parathyroid hormone stimulates the endothelial nitric oxide synthase through protein kinase A and C pathways. Nephrol Dial Transplant 10:2831–2837
26. Rashid G, Bernheim J, Green J, Benchetrit S (2008) Parathyroid hormone stimulates the endothelial expression of vascular endothelial growth factor. Eur J Clin Invest 38(11):798–803
27. Prisby RD, Ramsey MW, Behnke BJ, Dominguez JM, Donato AJ, Allen MR, Delp MD (2007) Aging reduces skeletal blood flow, endothelium-dependent vasodilation and nitric oxide bioavailability in rats. J Bone Miner Res 22:1280–1288
28. Sutliff R, Weber CS, Qian J, Miller ML, Clemens TL, Paul RJ (1999) Vasorelaxant properties of parathyroid hormone-related protein in the mouse: evidence for endothelium involvement independent of nitric oxide formation. Endocrinology 140(5):2077–2083
29. Mok L, Ajiwe E, Martin TJ, Thompson JC, Cooper CW (1989) Parathyroid hormone-related protein relaxes rat gastric smooth muscle and shows cross-desensitization with parathyroid hormone. J Bone Miner Res 4(3):433–439
30. Yamamoto M, Harm SC, Grasser WA, Thiede MA (1992) Parathyroid hormone-related protein in the rat urinary bladder: a smooth muscle relaxant produced locally in response to mechanical stretch. Proc Natl Acad Sci U S A 89:5326–5330
31. Thiede M, Daifotis AG, Weir EC, Brines ML, Burtis WJ, Ikeda K, Dreyer BE, Garfield RE, Broadus AE (1990) Intrauterine occupancy controls expression of the parathyroid hormone-related peptide gene in preterm rat myometrium. Proc Natl Acad Sci U S A 87(18):6969–6973
32. Cochrane E, McCarthy ID (1991) Rapid effects of parathyroid hormone (1–34) and prostaglandin E2 on bone blood flow and strontium clearance in the rat in vivo. J Endocrinol 131(3):359–365
33. Roche B, Vanden-Bossche A, Malaval L, Normand M, Jannot M, Chaux R, Vico L, Lafage-Proust MH (2014) Parathyroid hormone 1–84 targets bone vascular structure and perfusion in mice: impacts of its administration regimen and of ovariectomy. J Bone Miner Res 29(7):1608–1618
34. Driessens M, Vanhoutte PM (1981) Effect of calcitonin, hydrocortisone, and parathyroid hormone on canine bone blood vessels. Am J Physiol 241(1):H91–H94
35. Stabley J, Prisby RD, Behnke BJ, Delp MD (2013) Chronic skeletal unloading of the rat femur: mechanisms and functional consequences of vascular remodeling. Bone 57(2):355–360
36. Behnke B, Prisby RD, Lesniewski LA, Donato AJ, Olin HM, Delp MD (2006) Influence of ageing and physical activity on vascular morphology in rat skeletal muscle. J Physiol 575(Pt 2):617–626
37. Shan J, Pang PK, Lin HC, Yang MC (1994) Cardiovascular effects of human parathyroid hormone and parathyroid hormone-related peptide. J Cardiovasc Pharmacol 23(Suppl 2):S38–S41
38. Winquist R, Baskin EP, Vlasuk GP (1987) Synthetic tumor-derived human hypercalcemic factor exhibits parathyroid hormone-like vasorelaxation in renal arteries. Biochem Biophys Res Commun 149(1):227–232
39. Kishimoto H, Tsumura K, Fujioka S, Uchimoto S, Yamashita N, Suzuki R, Yoshimaru K, Shimura M, Sasakawa O, Morii H (1991) Effects of parathyroid hormone-related protein on systemic and regional hemodynamics in conscious rats. A comparison with human parathyroid hormone. Contrib Nephrol 90:72–78
40. Crass M 3rd, Jayaseelan CL, Darter TC (1987) Effects of parathyroid hormone on blood flow in different regional circulations. Am J Physiol 253(4 Pt 2):R634–R639
41. Prosser C, Farr VC, Davis SR (1994) Increased mammary blood flow in the lactating goat induced by parathyroid hormone-related protein. Exp Physiol 79(4):565–570
42. Moseley J, Kubota M, Diefenbach-Jagger H, Wettenhall RE, Kemp BE, Suva LJ, Rodda CP, Ebeling PR, Hudson PJ, Zajac JD, Martin TJ (1987) Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci U S A 84(14):5048–5052
43. Vargas S, Gillespie MT, Powell GJ, Southby J, Danks JA, Moseley JM, Martin TJ (1992) Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization. J Bone Miner Res 7(8):971–979
44. Kitazawa S, Fukase M, Kitazawa R, Takenaka A, Gotoh A, Fujita T, Maeda S (1991) Immunohistologic evaluation of parathyroid hormone-related protein in human lung cancer and normal tissue with newly developed monoclonal antibody. Cancer 67(4):984–989
45. Isowa S, Shimo T, Ibaragi S, Kurio N, Okui T, Matsubara K, Hassan NM, Kishimoto K, Sasaki A (2010) PTHrP regulates angiogenesis and bone resorption via VEGF expression. Anticancer Res 30(7):2755–2767
46. Gunther C, Legowski PA, Lyle RM, Weaver CM, McCabe LD, McCabe GP, Peacock M, Teegarden D (2006) Parathyroid hormone is associated with decreased fat mass in young healthy women. Int J Obes Lond 30(1):94–99
47. Yan J, Sun W, Zhang J, Goltzman D, Miao D (2012) Bone marrow ablation demonstrates that excess endogenous parathyroid hormone plays distinct roles in trabecular and cortical bone. Am J Pathol 181(1):234–244
48. Clarke B, Kay Berg J, Fox J, Cyran JA, Lagast H (2014) Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1–84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study. Clin Ther 36(5):722–736
49. Chu N, Li XN, Chen WL, Xu HR (2007) Pharmacokinetics and safety of recombinant human parathyroid hormone (1–34) (teriparatide) after single ascending doses in Chinese healthy volunteers. Pharmazie 62(11):869–871
50. Isales C, Sumpio B, Bollag RJ, Zhong Q, Ding KH, Du W, Rodriguez-Commes J, Lopez R, Rosales OR, Gasalla-Herraiz J, McCarthy R, Barrett PQ (2000) Functional parathyroid hormone receptors are present in an umbilical vein endothelial cell line. Am J Physiol Endocrinol Metab 279(3):E654–E662
51. Usdin T, Hilton J, Vertesi T, Harta G, Segre G, Mezey E (1999) Distribution of the parathyroid hormone 2 receptor in rat: immunolocalization reveals expression by several endocrine cells. Endocrinology 140(7):3363–3371
52. Usdin T, Gruber C, Bonner TI (1995) Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. J Biol Chem 270(26):15455–15458
53. Usdin T, Hoare SR, Wang T, Mezey E, Kowalak JA (1999) TIP39: a new neuropeptide and PTH2-receptor agonist from hypothalamus. Nat Neurosci 2(11):941–933
54. Kalinowski L, Dobrucki LW, Malinski T (2001) Nitric oxide as a second messenger in parathyroid hormone-related protein signaling. J Endocrinol 170:433–440
55. Throckmorton D, Kurscheid-Reich D, Rosales OR, Rodriguez-Commes J, Lopez R, Sumpio B, Zhong Q, Ding KH, McCarthy R, Barrett PQ, Isales CM (2002) Parathyroid hormone effects on signaling pathways in endothelial cells vary with peptide concentration. Peptides 23(1):79–85
56. Wang H, Drugge ED, Yen YC, Blumenthal MR, Pang PK (1984) Effects of synthetic parathyroid hormone on hemodynamics and regional blood flows. Eur J Pharmacol 97(3–4):209–215